Health Canada Approves Cytokinetics’ MYQORZO for Symptomatic oHCM

Health Canada issued a Notice of Compliance authorizing Cytokinetics’ aficamten treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy.